These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

227 related articles for article (PubMed ID: 11857305)

  • 1. Detection of cell free Epstein-Barr virus DNA in sera from patients with nasopharyngeal carcinoma.
    Hsiao JR; Jin YT; Tsai ST
    Cancer; 2002 Feb; 94(3):723-9. PubMed ID: 11857305
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of plasma Epstein-Barr virus (EBV) DNA levels and serum EBV immunoglobulin A/virus capsid antigen antibody titers in patients with nasopharyngeal carcinoma.
    Shao JY; Li YH; Gao HY; Wu QL; Cui NJ; Zhang L; Cheng G; Hu LF; Ernberg I; Zeng YX
    Cancer; 2004 Mar; 100(6):1162-70. PubMed ID: 15022282
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Significance of cell-free Epstein-Barr virus DNA in monitoring prognosis of nasopharyngeal carcinoma].
    Cao SM; Min HQ; Gao JS; Hong MH; Xiao XB; Zhang CQ; Liu XD; Zhang AL; Guo X
    Ai Zheng; 2003 Mar; 22(3):302-6. PubMed ID: 12654192
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Presence of Epstein-Barr virus latent membrane protein 1 gene in the nasopharyngeal swabs from patients with nasopharyngeal carcinoma.
    Lin SY; Tsang NM; Kao SC; Hsieh YL; Chen YP; Tsai CS; Kuo TT; Hao SP; Chen IH; Hong JH
    Head Neck; 2001 Mar; 23(3):194-200. PubMed ID: 11428449
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pretherapy quantitative measurement of circulating Epstein-Barr virus DNA is predictive of posttherapy distant failure in patients with early-stage nasopharyngeal carcinoma of undifferentiated type.
    Leung SF; Chan AT; Zee B; Ma B; Chan LY; Johnson PJ; Lo YM
    Cancer; 2003 Jul; 98(2):288-91. PubMed ID: 12872347
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Quantitative Epstein-Barr virus DNA analysis and detection of gene promoter hypermethylation in nasopharyngeal (NP) brushing samples from patients with NP carcinoma.
    Tong JH; Tsang RK; Lo KW; Woo JK; Kwong J; Chan MW; Chang AR; van Hasselt CA; Huang DP; To KF
    Clin Cancer Res; 2002 Aug; 8(8):2612-9. PubMed ID: 12171892
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Application of circulating plasma/serum EBV DNA in the clinical management of nasopharyngeal carcinoma.
    Yip TT; Ngan RK; Fong AH; Law SC
    Oral Oncol; 2014 Jun; 50(6):527-38. PubMed ID: 24440146
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic value of plasma Epstein-Barr virus DNA level during posttreatment follow-up in the patients with nasopharyngeal carcinoma having undergone intensity-modulated radiotherapy.
    Li WF; Zhang Y; Huang XB; Du XJ; Tang LL; Chen L; Peng H; Guo R; Sun Y; Ma J
    Chin J Cancer; 2017 Nov; 36(1):87. PubMed ID: 29116021
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Noninvasive diagnosis of nasopharyngeal carcinoma: nasopharyngeal brushings reveal high Epstein-Barr virus DNA load and carcinoma-specific viral BARF1 mRNA.
    Stevens SJ; Verkuijlen SA; Hariwiyanto B; Harijadi ; Paramita DK; Fachiroh J; Adham M; Tan IB; Haryana SM; Middeldorp JM
    Int J Cancer; 2006 Aug; 119(3):608-14. PubMed ID: 16572427
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Quantitative analysis of plasma Epstein-Barr virus (EBV) DNA for monitoring of recurrence and metastasis in nasopharyngeal carcinoma patients after radiotherapy].
    Li YH; Shao JY; Zhao MQ; Gao HY; Li LR; Guan ZZ; Zeng YX
    Ai Zheng; 2003 Jun; 22(6):645-8. PubMed ID: 12948418
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Role of Epstein-Barr virus DNA measurement in plasma in the clinical management of nasopharyngeal carcinoma in a low risk area.
    Kalpoe JS; Dekker PB; van Krieken JH; Baatenburg de Jong RJ; Kroes AC
    J Clin Pathol; 2006 May; 59(5):537-41. PubMed ID: 16489178
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Disparity of sensitivities in detection of radiation-naïve and postirradiation recurrent nasopharyngeal carcinoma of the undifferentiated type by quantitative analysis of circulating Epstein-Barr virus DNA1,2.
    Leung SF; Lo YM; Chan AT; To KF; To E; Chan LY; Zee B; Huang DP; Johnson PJ
    Clin Cancer Res; 2003 Aug; 9(9):3431-4. PubMed ID: 12960133
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Quantitative analysis of plasma cell-free Epstein-Barr virus DNA in nasopharyngeal carcinoma after salvage nasopharyngectomy: a prospective study.
    Wei WI; Yuen AP; Ng RW; Ho WK; Kwong DL; Sham JS
    Head Neck; 2004 Oct; 26(10):878-83. PubMed ID: 15390201
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Prognostic impact of plasma Epstein-Barr virus DNA concentration on distant metastasis in nasopharyngeal carcinoma].
    Hou X; Zhang L; Zhao C; Li S; Lu LX; Han F; Shao JY; Huang PY
    Ai Zheng; 2006 Jul; 25(7):785-92. PubMed ID: 16831265
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of clinical and molecular surveillance in patients with advanced nasopharyngeal carcinoma after primary therapy: the potential role of quantitative analysis of circulating Epstein-Barr virus DNA.
    Hong RL; Lin CY; Ting LL; Ko JY; Hsu MM
    Cancer; 2004 Apr; 100(7):1429-37. PubMed ID: 15042677
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Different prognostic values of plasma Epstein-Barr virus DNA and maximal standardized uptake value of 18F-FDG PET/CT for nasopharyngeal carcinoma patients with recurrence.
    Shen T; Tang LQ; Luo DH; Chen QY; Li PJ; Mai DM; Guo SS; Liu LT; Qian CN; Guo X; Zeng MS; Mo HY; Mai HQ
    PLoS One; 2015; 10(4):e0122756. PubMed ID: 25853677
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Laboratory markers of tumor burden in nasopharyngeal carcinoma: a comparison of viral load and serologic tests for Epstein-Barr virus.
    Fan H; Nicholls J; Chua D; Chan KH; Sham J; Lee S; Gulley ML
    Int J Cancer; 2004 Dec; 112(6):1036-41. PubMed ID: 15386346
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Quantitative and temporal correlation between circulating cell-free Epstein-Barr virus DNA and tumor recurrence in nasopharyngeal carcinoma.
    Lo YM; Chan LY; Chan AT; Leung SF; Lo KW; Zhang J; Lee JC; Hjelm NM; Johnson PJ; Huang DP
    Cancer Res; 1999 Nov; 59(21):5452-5. PubMed ID: 10554016
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of plasma Epstein-Barr virus DNA load to distinguish nasopharyngeal carcinoma patients from healthy high-risk populations in Southern China.
    Ji MF; Huang QH; Yu X; Liu Z; Li X; Zhang LF; Wang P; Xie SH; Rao HL; Fang F; Guo X; Liu Q; Hong MH; Ye W; Zeng YX; Cao SM
    Cancer; 2014 May; 120(9):1353-60. PubMed ID: 24477877
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-term monitoring of dynamic changes in plasma EBV DNA for improved prognosis prediction of nasopharyngeal carcinoma.
    Li W; Chen J; Liang B; Li Z; Li J; Yuan X; Wu S; Zeng F; Peng X; Li Y; Lu J; Zhao F; Liu X
    Cancer Med; 2021 Feb; 10(3):883-894. PubMed ID: 33378109
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.